Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin
These data suggest that among people living with T2D treated with metformin who require a second glucose-lowering therapy, GLP-1RAs may reduce or delay the need for further treatment intensification versus other standard glucose-lowering therapies.
Authors
- Christian Kruse (ORCID: https://orcid.org/0000-0001-5590-2245)
- Vanita R. Aroda (ORCID: https://orcid.org/0000-0002-7706-4585)
- Uffe Christian Braae (ORCID: https://orcid.org/0000-0002-2743-4584)
- John W. Ostrominski (ORCID: https://orcid.org/0000-0002-2866-9414)
- John B. Buse (ORCID: https://orcid.org/0000-0002-9723-3876)
- Kabirdev Mandavya
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (India) (IN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1007/s13300-025-01751-6
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Novo Nordisk